Tagged with Pricing,

China Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. Together with his colleague Sarah Hassan, a researcher at the company they look at China’s skyrocketing health industry and what to expect from it in the Year of the Pig, 2019.    China approved a record 48 new drugs last year, despite a significant organizational restructuring.…

India Anay Shukla leads the pharmaceutical, life sciences, med-tech and healthcare practice at Nishith Desai Associates, a leading Indian law firm. In this article, he examines the benefit of the recent policy changes to price controls for innovative drugs in India.  Unlike many other countries, India controls prices of all drugs…

China In late 2018 China adopted a novel procurement scheme with the aim of dramatically cutting the amount being paid for generic drugs. The policy’s effect on pricing stands to hit domestic generic firms hardest unless they adapt their business models. Big Pharma could also lose out as their off-patent originators…

France Maurice-Pierre Planel, president of the CEPS (Comité économique des produits de santé), details how the French government is unique in the way that they engage in drug pricing and comments on how the transformation of the French healthcare system will impact the CEPS’s role in price negotiation.   You are…

Regulation Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) in the United States, discusses the contradictory nature of Trump’s efforts to lower drug prices.    The President has forcefully pledged to provide relief to these patients and their families, but his own trade policy threatens…

Baltics Marina Truhanova, deputy head of National Health Service Latvia, discusses the responsibility that the Latvian National Health System (NHS) has in terms of allocating their financial resources wisely, the importance of public procurement of medicines with the other two Baltic states to purchase cheaper drugs and allow for more access…

Canada Imran Ali, senior manager of the pan-Canadian Pharmaceutical Alliance (pCPA) Office, the body that provides dedicated centralized support to the national negotiating process for drug prices, representing all 14 public drug plan jurisdictions in Canada, discusses the mandate of the pCPA, the main achievements so far, as well as the…

Canada Taiho Pharmaceutical Co., Ltd. (TPC), Japan, part of Otsuka Holdings, established its Canadian affiliate in 2017. Ross Glover, general manager for Taiho Pharma Canada, has spent the past year tackling the mammoth task of establishing the foundations for the operations, including preparing a new drug for market approval and navigating…

Lithuania Darius Sinkevičius, chairman of the board at the Lithuanian Association of Generic Pharmaceuticals Manufacturers (VGA), explains the main trends impacting the generic pharmaceutical industry in the country as well as the role of off-patent medicines in creating savings for the Lithuanian healthcare system. Can you give to our international audience…

Switzerland In an exclusive interview, Bruno Strigini, global CEO of Novartis Oncology, discusses the logic of the company’s separate oncology business unit, the significance of US FDA approval for the new CAR-T cell therapy, Kymriah, and the issues around pricing for this revolutionary treatment.   * Please note that this interview was…

Poland Sabina Sampławska, director, head of life sciences at KPMG Poland, discusses the challenge of pricing pressures and how their innovative services help companies manage this trend, as well as the need for data transparency in constructing correct strategies for clients. She also highlights the role KPMG is playing in bringing…

Poland Marcin Czech, deputy minister and undersecretary of state at the Polish Ministry of Health, provides an in-depth perspective on Poland’s drug policy framework and the new medicines policy that aims to integrate pharmacoecomonics to ensure Poland can find an efficient balance between innovative and generic treatments for long-term stability. Furthermore,…